Company intelligence / Profile preview
Parion Sciences
Durham, North Carolina, USAparion.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
Parion Sciences has reported positive Phase 2 clinical results for its lead program targeting Primary Ciliary Dyskinesia with Idrevloride inhalation solution. The company received orphan drug designation from the European Medicines Agency for this indication and positive regulatory feedback on pediatric investigation plans. Their approach centers on restoring innate mucosal surface defenses in lung and eye through ENaC inhibition.
- Therapeutic areas
- OphthalmologyPulmonologyRare Diseases
- Modalities
- Small molecules (notably ENaC blockers)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Parion Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Parion Sciences.